Ignite Creation Date:
2025-12-24 @ 9:48 PM
Ignite Modification Date:
2026-05-29 @ 10:14 AM
Study NCT ID:
NCT04597632
Status:
COMPLETED
Last Update Posted:
2024-10-09
First Post:
2020-10-01
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Neovascular Age-related Macular Degeneration | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | neovascular age-related macular degeneration | View |
| None | wet age-related macular degeneration | View |
| None | wet AMD | View |
| None | choroidal neovascularization | View |
| None | individualized treatment | View |
| None | anti-VEGF | View |
| None | Macular degeneration | View |
| None | age-related macular degeneration (ARMD) | View |
| None | vision loss | View |
| None | macula damage | View |
| None | retina damage | View |
| None | dry macular degeneration | View |
| None | wet macular degeneration | View |
| None | Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration | View |